Everything NICE has said on the acute management of myocardial infarction with ST-segment elevation in an interactive flowchart
Everything NICE has said on cardiac rehabilitation and preventing cardiovascular disease after myocardial infarction in an interactive flowchart
This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction. It aims to promote the health of people who have had an MI by encouraging them to attend a cardiac rehabilitation programme and advising them on a healthy lifestyle. It also includes advice on drug therapy.
This guideline covers care and treatment of people aged 18 and over with a type of heart attack known as spontaneous onset of myocardial infarction with ST-segment elevation (STEMI). It aims to ensure that adults with STEMI are assessed and treated as soon as possible to minimise the damage to their heart. It also aims to help commissioners and healthcare professionals configure services so that people with STEMI can have the best outcomes.
This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)
Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)
Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)
This guideline covers treatments for people aged 18 and over with unstable angina (recurring chest pain) or a type of heart attack called non-ST-segment-elevation myocardial infarction (NSTEMI). It aims to ensure that people get treatment quickly. It recommends that as soon as NSTEMI or unstable angina is diagnosed, healthcare professionals assess people for risk of more serious heart problems in the future to guide their treatment.
This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in
This guideline covers the link between body mass index (BMI) and waist circumference and the risk of disease among adults from black, Asian and other minority ethnic groups in the UK. The aim was to determine whether lower cut-off points should be used for these groups as a trigger for lifestyle interventions to prevent conditions such as diabetes, myocardial infarction or stroke.
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
This guideline covers managing hyperglycaemia in the first 48 hours for adults admitted to hospital for acute coronary syndromes. It aims to improve initial management of hyperglycaemia and ensure that adults are given advice on their diabetes risk and how to reduce it.
Everything NICE has said on assessing and managing recent suspected cardiac chest pain including acute coronary syndromes and stable angina in an interactive flowchart
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)
Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting in coronary artery disease (CAD)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery
Evidence-based recommendations on bioresorbable stent implantation for treating coronary artery disease (CHD)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)
Evidence-based recommendations on transmyocardial laser revascularisation (TMLR) for refractory angina pectoris
Evidence-based recommendations on percutaneous laser revascularisation (keyhole surgery) for refractory angina pectoris
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB)
Evidence-based recommendations on off-pump coronary artery bypass grafting (CABG) to treat coronary artery disease (CAD)
Evidence-based recommendations on percutaneous laser coronary angioplasty to treat blocked coronary arteries
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary
In development [GID-NG10085] Expected publication date: 14 May 2020
Advice ClearWay RX for drug delivery to coronary artery thrombotic lesions to aid local decision-making
Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension
Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia in patients having abdominal surgery
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
hypertension , chronic heart failure , chronic kidney disease , myocardial infarction – secondary prevention , type 1 diabetes and type...
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Advice on the use of the PressureWire fractional flow reserve measurement system for coronary artery disease to aid local decision-making
Evidence-based recommendations on ultrasound-guided foam sclerotherapy for treating varicose veins
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults
Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart
Admissions rates due to myocardial infarction in people with diabetes Subject(s): Diabetes Date of publication: 01